Eyeworld Daily News

61 EW SHOW DAILY ASCRS•ASOA Symposium & Congress, Los Angeles 2017 hold the collar and pull the device gently back into the AC until the correct position is reached. "I am the cataract surgeon among my glaucoma colleagues," Dr. Tyson said, referencing his panel. "What that means is, if I can do it, you can do it. You don't have to be a glaucoma specialist to do CyPass." Richard Lewis, MD, Sacramen- to, California, presented results of the COMPASS trial, which, he said, was the first to conform to FDA guidance and ANSI standards for a MIGS implant in mild to moderate glaucoma. It was also the largest surgical study of its kind to date, Dr. Lewis said. Study participants included those with primary open angle glaucoma, a Schaffer grade 3–4 grade angle, and unmedicated diurnal IOP between 21–33 mm Hg. The control (phaco only) group included 131 pa- tients, while the study (CyPass and phaco) group included 374 patients. At 2 years postop, 72.5% of eyes achieved an unmedicated diurnal IOP reduction of 20% or more in the study group (58% in the control group); 61.2% of eyes maintained an unmedicated IOP range between 6 and 18 mm Hg during this time- frame (43.5% in the control group). Intraoperative adverse events occurred in 5% of CyPass cases in the study. Postoperative adverse events occurred in 39% of CyPass cases, while the phaco alone group saw adverse events 36% of the time. An audience member asked, giv- en the similar indications between iStent (Glaukos, San Clemente, California) and CyPass, how do you choose which one to use? Dr. Lewis said that CyPass could have advan- tages in patients with somewhat nar- rower angles or in cases where there could be downstream problems in the canal. Dr. Sarkisian said he thinks sur- geons should get comfortable with all of the different MIGS options. "If you're in the war, you need to suit up with everything you've got and go in with eyes wide open and be ready for everything. Part of that is being able to use all of the technology. Once you do that, you'll know what's going to work best in your hands," he said. EW Editors' note: This event was sponsored by Alcon. Indication LOTEMAX ® GEL (loteprednol etabonate ophthalmic gel) 0.5% is indicated for the treatment of post-operative infl ammation and pain following ocular surgery. Important Safety Information about LOTEMAX ® GEL • LOTEMAX ® GEL is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. • Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. If this product is used for 10 days or longer, IOP should be monitored. • Use of corticosteroids may result in posterior subcapsular cataract formation. • Use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation and occurrence of perforations in those with diseases causing corneal and scleral thinning. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, and where appropriate, fluorescein staining. • Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infection. In acute purulent conditions, steroids may mask infection or enhance existing infection. • Use of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and exacerbate the severity of many viral infections of the eye (including herpes simplex). • Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. • Patients should not wear contact lenses when using LOTEMAX ® GEL. • The most common ocular adverse drug reactions reported were anterior chamber inflammation (5%), eye pain (2%) and foreign body sensation (2%). Please see brief summary of Prescribing Information on adjacent page. ®/™ are trademarks of Bausch & Lomb Incorporated or its a liates. © 2015 Bausch & Lomb Incorporated. All rights reserved. Printed in USA. US/LGX/15/0041(1) Down, Boy. Help Tame Postoperative Ocular Inflammation and Pain With LOTEMAX ® GEL Dr. Samuelson highlights some of the main features of the CyPass supraciliary microstent.

• Cover